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after SR and further to 65 ± 1.8 bpm after REC. In addition, 
whole day low-frequency to-high frequency (LF/HF) power 
ratio of heart rate variability increased from 4.6 ± 0.4 at BL 
to 6.0 ± 0.6 after SR. Other parameters, including salivary 
NPY and cortisol levels, remained unaffected.
Conclusions Increased heart rate and LF/HF power ratio 
are early signs of an increased sympathetic activity after 
prolonged sleep restriction. To reliably interpret the clinical 
significance of these early signs of physiological stress, a 
follow-up study would be needed to evaluate if the stress 
responses escalate and lead to more unfavourable reactions, 
such as elevated blood pressure and a subsequent elevated 
risk for cardiovascular health problems.
Keywords Sleep restriction · Autonomic nervous 
system · HPA-axis · Cortisol · Heart rate variability
Introduction
The restorative function of sleep in many of our bodily sys-
tems, including the immune and cardiovascular systems, has 
been widely documented [1–5]. Despite the clear benefi-
cial functions of sleep, voluntary sleep restriction is getting 
increasingly common in modern industrialized societies, due 
to, for instance, increasing access to electronic entertain-
ment at times that were originally devoted to sleep [6]. In 
addition, atypical and excessive working hours contribute 
to sleep restriction in the working population [7–9]. Finally, 
restricted sleep is a common phenomenon among those suf-
fering from certain psychiatric or physical disorders [10].
The consequences of insufficient sleep are severe and 
widespread [11]. First of all, it results in sleepiness that con-
tributes to increasing amounts of traffic and work-related 
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accidents [12–15]. Sleep restriction also has adverse effects 
on mood and cognitive performance [16–19].
Probably the most serious direct effects, however, are 
those on health and bodily systems. Within the immune 
system, for instance, inflammatory markers rise in response 
to restricted sleep making it a risk factor for cardiovascular 
diseases [20–23]. It has also been shown that short sleep per 
se is associated with an increased mortality risk [24, 25].
Hence, it is important to unravel the mechanisms through 
which sleep and health are related to find ways and strategies 
to help people with chronically restricted sleep and patients 
with sleep disorders.
Stress systems allow us to adapt to a changing and/or 
challenging situation to maximize the likelihood of survival. 
Acute total sleep loss is an example of such a situation and 
it is therefore not surprising that the activity of the two main 
neuroendocrine systems of the integrated stress response 
(i.e., the autonomic sympatho-adrenal system and the hypo-
thalamic pituitary–adrenal axis) responds.
Although many studies have investigated how acute total 
sleep loss affects stress systems, the results are far from con-
sistent. Several studies have, for instance, failed to show an 
effect of total sleep loss on cortisol profiles [26–29], whereas 
others point towards an increase in cortisol levels [30, 31]. 
Studies on the effects of acute total sleep loss on heart rate 
show also inconsistent results. Some studies point toward 
increased heart rate in response to total sleep loss [32], oth-
ers to a decrease [33] and yet others to no effect at all [34].
Autonomic nervous system activity, as measured by heart 
rate variability (HRV), has been shown to change toward 
increased sympathetic activity after total sleep loss [32, 33, 
35, 36]. Pagani et al. however, could not confirm such a shift 
toward increased sympathetic activity [34].
Much fewer studies have been carried out adopting a 
prolonged partial sleep loss design. Pejovic and colleagues 
did not observe changes in cortisol levels after six nights of 
6 h sleep [37], whereas for instance Spiegel and colleagues 
have reported increased evening cortisol levels after six 
nights of 4 h sleep, but only when compared with a 12 h 
sleep extension condition [38]. Also regarding blood pres-
sure, previous studies are far from consistent. Dettoni et al. 
found all hemodynamic parameters to be unaffected after 
five nights of restricted sleep [39], whereas Tochikubo et al. 
have reported an increase in blood pressure after a night with 
restricted sleep [40].
Concerning HRV effects, some studies point toward an 
increase in sympathetic activity [39, 41], whereas others 
failed to show such an increase [38]. None of these studies, 
however, have adopted a design that reflects a situation that 
could occur during a working week.
Since prolonged partial sleep restriction is very common 
in working life, it is vital to fully understand how such a 
condition affects our stress systems. As described above, 
previous knowledge is not consistent. Therefore, in the pre-
sent study, we simulated accumulating sleep restriction dur-
ing five working days followed by 2 days of weekend recov-
ery sleep and measured the changes in several parameters of 
both the autonomic sympatho-adrenal system and the hypo-
thalamic pituitary–adrenal (HPA) axis that occurred dur-
ing this period. Previously, we have revealed that this sleep 
restriction design disturbs immune and metabolic functions 
as well as cognitive task performance and self-perception 
of cognitive performance [19, 22, 42, 43]. Hence, we here 
hypothesize (1) increased activity in both components of 
the integrated stress response and (2) increased sympathetic 
and decreased parasympathetic modulation in line with the 
results of Dettoni et al. [39].
Materials and methods
Participants and design
23 healthy men, aged 19–29  years (mean ± SD 
23.1 ± 2.5  years), participated in this study and were 
recruited during a 2-year time span. After a telephone inter-
view, participants underwent a thorough physical examina-
tion including blood tests (triglycerides, cholesterol, hae-
moglobin, creatinine, leukocytes, erythrocytes, hematocrit, 
TSH, ASAT, ALAT, MCV, MCH, and MCHC) and screen-
ing polysomnography. Final eligibility was evaluated accord-
ing to pre-determined inclusion and exclusion criteria, as 
described earlier [43]. Two weeks prior to the experiment, 
participants completed sleep diaries, had an adaptation 
night in the sleep laboratory, and carried actigraphs to ver-
ify adherence to a regular sleep–wake schedule (i.e., sleep 
between 2300 and 0700 hours). The pre-study actigraphy-
based mean sleep duration (±SD) was 6.88 (±0.58) h in the 
control group and 7.05 (±0.80) h in the experimental group.
The study design was approved by the ethics committee 
of Helsinki University Central Hospital and written informed 
consent was obtained from participants. The experiment was 
conducted at the Brain and Work Research Centre of the 
Finnish Institute of Occupational Health.
15 participants, who were randomly allocated to the 
experimental group (EXP), spent the first two nights 8 h 
in bed (baseline, BL; from 2300 to 0700 hours), followed 
by five nights of 4 h in bed (sleep restriction, SR; from 
0300 to 0700 hours), and, finally, again three nights of 8 h 
in bed (recovery, REC; Fig. 1). The remaining eight par-
ticipants served as the control group (CON) and spent 8 h 
in bed every night. Sleep during daytime was not allowed, 
which was monitored by continuous EEG recordings and 
a continuously present investigator. During waking, par-
ticipants took part in a bigger experiment of our sleep 
laboratory, involving the simulation of a working week by 
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a variety of cognitive and psychological tasks, also during 
the nights that were subject to restricted sleep.
Participants ate standardized meals at fixed times 
throughout the experiment: breakfast at 0800  hours 
(600  kcal), lunch at 1230  hours (800  kcal), dinner 
at 1830  hours (700  kcal), and snacks at 1530  hours 
(300 kcal) and 2130 hours (200 kcal). In addition, par-
ticipants in EXP ate a piece of fruit (apple or orange) at 
0030 hours (50 kcal). Participants were not allowed to 
leave the building, but could, during regular short breaks, 
leave the sleep and test room and visit a spare time room 
with a television and a personal computer.
Illumination in the sleep and test room ranged, at all 
times, from 150 to 400 L and in the spare time room from 
350 to 600 L The temperature ranged from 19 to 23 °C. 
Caffeine consumption was neither allowed during the 
experiment nor 1 week before. Non-caloric fluid intake 
(e.g., water) was not subject to any limitations.
Heart rate, blood pressure, and cardiac autonomic 
control measurements
The cardiac autonomic control was evaluated by 10 min 
recordings at supine rest between 0800 and 0900 hours. 
During this test period, interbeat intervals of cardiac func-
tion were registered continuously by the electrocardiogram 
(ECG, WinAcq, Absolute Aliens, Finland) and the periph-
eral blood pressure was monitored by photopletysmographic 
method (Portapres, Finapres Medical Systems, The Neth-
erlands). The circulatory parameters were calculated with 
special software of neurocardiological analyses (WinCPRS, 
Absolute Aliens, Finland) [44, 45].
The following parameters were assessed directly: RR 
intervals (RRIs), heart rate, systolic blood pressure, diastolic 
blood pressure, mean arterial pressure and pulse pressure. 
Stroke volume and cardiac output were calculated from these 
directly assessed data. In addition, the following components 
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Fig. 1  The experimental protocol. After two nights of 8 h TIB (base-
line, BL), TIB was restricted to 4  h per night for five subsequent 
nights (sleep restriction, SR), followed by three nights of 8  h TIB 
(recovery, REC). Profile days where measurements took place are 
shaded in gray. The lower panel shows a profile day in more detail
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included in measuring short-term spectral analysis (FFT 
method) of HRV and blood pressure variability: total power, 
ultralow-frequency (ULF, <0.0033 Hz) power, very low-
frequency (VLF, 0.0033 to <0.04 Hz) power, low-frequency 
(LF, 0.04 to <0.15 Hz) power, and high-frequency (HF, 0.15 
to <0.40 Hz) power.
Heart rate variability measurements
Whole day HRV measurements were done on the three 
profile days indicated in Fig. 1. On these days, HRV was 
determined during 5-min epochs that were selected about 
every 2 h (i.e., at approximately 0800, 1000, 1200, 1400, 
1600, 1800, 2000, and 2200 hours) when subjects were sit-
ting during the rest periods between the cognitive task ses-
sions. Ambulatory ECG was recorded at 200 Hz and ana-
lyzed using Somnologica Studio Software (Version 3.3.1, 
Medcare, Reykjavik, Iceland). RRIs during the epochs were 
detected by Somnologica and checked for artifact correction 
and rejection according to established standards [45, 46] 
and stored in an RRI ASCII file. From the RRI file, power 
spectral density (PSD) was calculated, using Kubios HRV 
Software 1.16 (University of Kuopio, Kuopio, Finland), with 
the default parametric autoregressive model. Powers were 
calculated for different frequency bands: very low frequency 
(VLF, 0–0.04 Hz), low frequency (LF, 0.04–0.15 Hz), and 
high frequency (HF, 0.15–0.40 Hz) in absolute units (ms2), 
normalized units (n.u.) and as percentage of total power. 
In addition, the ratio between the LF and HF bands was 
calculated.
Salivary neuropeptide Y and cortisol assays
Saliva samples for the analysis of NPY levels were collected 
8 times a day on the three profile days (Fig. 1): at 0800, 
0950, 1240, 1400, 1600, 1800, 2000, and 2200 h. NPY lev-
els were measured using a commercial EIA immunoassay 
kit [Phoenix Pharmaceuticals, Inc; Neuropeptide Y (NPY); 
human, rat]. The measurement range was 0.10–100 ng/mL 
(linear range 0.1–1.4 ng/mL) with assay repeatability values 
of 5% (within series) and 8% (between series). These results 
are not absolute concentrations of NPY because of matrix 
effects (i.e., effects of other substances in the sample), but 
the samples of one participant at the three profile days are 
comparable.
Saliva samples for the analysis of cortisol levels were 
collected ten times a day on the three profile days (Fig. 1): 
at 0700, 0730, 0800, 0950, 1230, 1400, 1600, 1800, 2000, 
and 2200 hours. Cortisol levels were measured using a com-
mercial kit assay (Salivary Cortisol, LIA, IBL, Hamburg, 
Germany). The measurement range was 0.43–110 nmol/L 
with assay repeatability values of 5% (within series) and 8% 
(between series).
Statistical analysis
HRV, NPY, and cortisol levels were analyzed using 
repeated measures ANOVA to test for main effects of 
day, time, and day × time. For cortisol, due to the strong 
well-known morning peak, this was done separately for 
morning values (t ≤ 1230 hours) and for afternoon/evening 
values (t > 1230 hours). The other data that were meas-
ured only once per profile day were also analyzed using 
repeated measures ANOVA and tested for an effect of 
day. A p value <0.05 was considered to be statistically 
significant. For cortisol, outliers (>2 × SD from mean, 
n = 13) and missing values (n = 2) were replaced by the 
group mean value for that specific time point. Group (EXP 
or CON) was not included as factor in the ANOVA, due 
to highly unequal group sizes and consequently unequal 
standard deviations.
All statistical analyses were carried out using SPSS 
Statistics 19.0.0 for Mac OS X (IBM Corporation, New 
York, USA) and the figures were generated using Graph-
Pad Prism 5.0 for Mac OS X (GraphPad Software Inc., La 
Jolla, USA).
Results
Effectiveness of the protocol
To ensure the effectiveness of the sleep restriction pro-
tocol, participants rated their sleepiness levels using the 
Karolinska Sleepiness Scale (KSS) [47] 14 times on every 
test day. In EXP, the daily mean KSS score went from 
4.3 ± 0.3 at BL, to 6.2 ± 0.4 at SR, to 3.8 ± 0.4 at REC 
[F(2,24) = 21.98, p < .001]. In CON, the daily mean KSS 
scores did not change throughout the experiment.
Cardiovascular parameters
The results of the cardiovascular parameters are shown 
in Table 1 and Fig. 2. In CON, none of the parameters 
changed during the experiment and in EXP only heart 
rate rose significantly during the experiment (Fig. 2). The 
RRI declined from 1009 ± 27 ms at BL to 967 ± 15 ms at 
SR to 929 ± 23 ms at REC [F(2,22) = 9.89, p = .001]. In 
terms of beats per minute, this meant an increase from 
60 ± 1.8 bpm at BL to 63 ± 1.1 bpm at SR to 65 ± 1.8 bpm 
at REC [F(2,18) = 6.29, p = .008]. All other parameters, 
including blood pressure, remained unaffected (Table 1).
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Short‑term spectral analyses of blood pressure 
and heart rate variability
Blood pressure variability results are shown in Table 2 and 
HRV results are shown in Table 3. As can be seen, none 
of the components in either group changed significantly 
during the experiment.
Whole day heart rate variability
The LF/HF power ratio remained unaffected in CON, 
whereas in EXP it differed between the profile days 
[F(2,22) = 5.64, p = .011], with lowest at BL (4.6 ± 0.4) and 
peaking at SR (6.0 ± 0.6; Fig. 3c). In addition, a slight effect 
of time of day was observed [F(7,77) = 2.16, p = .047]. The 
Table 1  Basic cardiovascular parameters results
Values are means ± SE. F and p values indicate results of repeated measurements ANOVA. For abbreviations, refer to the text
Control group Experimental group
BL SR REC p BL SR REC p
RRI interval (ms) 1033 ± 112 1092 ± 158 1010 ± 135 F = 3.41, p = .227 1009 ± 27 967 ± 15 929 ± 23 F = 9.89, p = .001
Heart rate (bpm) 59 ± 6.3 56 ± 8.1 61 ± 8.0 F = 5.08, p = .164 60 ± 1.8 63 ± 1.1 65 ± 1.8 F = 6.29, p = .008
Systolic arterial pressure 
(mmHg)
120 ± 3.4 111 ± 8.5 107 ± 17 F = 1.03, p = .491 132 ± 5.0 127 ± 5.9 130 ± 6.6 F = 0.431, p = .655
Diastolic arterial pressure 
(mmHg)
48 ± 0.35 45 ± 1.8 42 ± 6.0 F = 0.940, p = .515 55 ± 3.3 55 ± 3.4 54 ± 2.9 F = 0.135, p = .874
Mean arterial pressure 
(mmHg)
67 ± 0.80 64 ± 3.1 60 ± 7.8 F = 0.965, p = .509 74 ± 3.5 74 ± 3.4 73 ± 3.4 F = 0.083, p = .921
Pulse pressure (mmHg) 72 ± 3.1 65 ± 6.7 65 ± 11 F = 1.23, p = .448 77 ± 2.9 72 ± 5.3 76 ± 5.2 F = 0.727, p = .496
Stroke volume (ml) 90 ± 7.2 86 ± 3.3 86 ± 2.7 F = 1.06, p = .486 84 ± 2.5 80 ± 2.5 84 ± 2.8 F = 1.20, p = .321
Cardiac output (L/min) 5.4 ± 0.98 4.9 ± 0.87 5.2 ± 0.84 F = 12.06, p = .077 5.1 ± 0.24 5.0 ± 0.15 5.5 ± 0.15 F = 2.47, p = .107
Fig. 2  RR interval (a), heart 
rate (b), arterial pressure 
(c), and pulse pressure (d) at 
baseline (BL), and after sleep 
restriction (SR) and recovery 
(REC) in the control group 
(CON) and the experimen-
tal group (EXP). Values are 
means ± SEM, **p < .01
A B
C D
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lowest levels were observed at 1800 hours (3.5 ± 0.4) and 
peak levels at 2000 hours (6.7 ± 0.9). Finally, there was a 
slight interaction between day and time [F(14,154) = 1.76, 
p = .049].
Salivary neuropeptide Y levels
The salivary NPY levels did not differ between the three 
profile days in either group. The levels did, however, change 
with time in both CON [F(7, 42) = 3.12, p = .010] and EXP 
[F(7, 91) = 10.70, p < .001]. In CON, the levels ranged from 
1.2 ± 0.18 at 0800 hours to 3.3 ± 0.60 at 1600 hours and in 
EXP it ranged from 0.74 ± 0.12 at 0800 hours to 2.3 ± 0.41 at 
1600 hours.
Salivary cortisol levels
For the morning values, a main effect of time was observed 
in both CON [F(4, 24) = 25.00, p < .001] and EXP [F(4, 
48) = 75.27, p < .001]. In CON, salivary cortisol values 
peaked at 0730 hours (34.6 ± 2.66 nmol/L) and were low-
est at 0950 hours (14.7 ± 3.10 nmol/L). In EXP, the cortisol 
values also peaked at 0730 hours (35.8 ± 2.67 nmol/L) and 
were lowest at 1230 hours (11.0 ± 1.07 nmol/L). Moreover, 
in EXP, an interaction was observed between day and time 
[F(8, 96) = 3.12, p = .004], indicating a phase shift. Indeed, 
the peak shifted forward after SR compared to BL, from 
0730 to 0800 hours, and subsequently back to 0730 hours 
again after REC.
Afternoon cortisol values showed no effects in CON, and 
a main effect of only time in EXP [F(4, 48) = 7.41, p < .001], 
where cortisol values declined from 11.6 ± 1.1 nmol/L at 
1400 hours to 5.8 ± 1.1 nmol/L at 2200 hours.
Discussion
Long-term sleep restriction is becoming an increasingly 
common phenomenon in modern industrialized socie-
ties, due to, for instance, increasing work demands and 
Table 2  Short-term spectral analysis of blood pressure variability (BPV) results
Values are means ± SE. F and p values indicate results of repeated measurements ANOVA. For abbreviations, refer to the text
Control group Experimental group
BL SR REC p BL SR REC p
Total power  (mmHg2) 24.2 ± 1.3 29.4 ± 5.3 33.6 ± 11 F = 0.346, p = .743 32.2 ± 6.3 61.2 ± 14 55.8 ± 7.7 F = 2.80, p = .083
ULF power  (mmHg2) 1.9 ± 1.2 1.1 ± 0.70 1.7 ± 1.5 F = 1.15, p = .465 3.1 ± 0.60 7.2 ± 2.6 6.1 ± 1.8 F = 1.19, p = .322
VLF power  (mmHg2) 15.6 ± 1.3 20.5 ± 2.1 22.2 ± 5.4 F = 0.709, p = .585 16.2 ± 4.7 40.5 ± 11 35.4 ± 6.6 F = 3.38, p = .053
LF power  (mmHg2) 4.4 ± 2.3 6.3 ± 3.3 7.9 ± 5.8 F = 0.150, p = .869 10.4 ± 2.3 10.2 ± 1.9 10.1 ± 1.3 F = 0.010, p = .990
HF power  (mmHg2) 2.4 ± 1.4 1.6 ± 0.80 1.9 ± 0.90 F = 1.58, p = .388 2.5 ± 0.75 3.3 ± 0.59 4.1 ± 1.0 F = 1.32, p = .287
LF/HF power (%) 196 ± 20 688 ± 565 354 ± 138 F = 0.464, p = .683 713 ± 212 370 ± 67 501 ± 147 F = 1.24, p = .309
Normalized LF power 0.66 ± 0.03 0.74 ± 0.19 0.76 ± 0.07 F = 0.156, p = .865 0.75 ± 0.06 0.74 ± 0.04 0.71 ± 0.05 F = 0.278, p = .760
Normalized HF power 0.34 ± 0.02 0.26 ± 0.19 0.24 ± 0.07 F = 0.149, p = .870 0.25 ± 0.06 0.26 ± 0.03 0.29 ± 0.05 F = 0.264, p = .770
Table 3  Short-term spectral analysis of heart rate variability (HRV) results
Values are means ± SE. F and p values indicate results of repeated measurements ANOVA. For abbreviations, refer to the text
Control group Experimental group
BL SR REC p BL SR REC p
Total power  (ms2) 3638 ± 770 4352 ± 2520 3309 ± 1098 F = 0.328, p = .753 4592 ± 945 5874 ± 2016 3995 ± 1331 F = 0.444, p = .647
ULF power  (ms2) 208 ± 12 356 ± 335 134 ± 86 F = 0.446, p = .692 202 ± 65 437 ± 301 113 ± 22 F = 0.927, p = .411
VLF power  (ms2) 955 ± 117 918 ± 537 779 ± 294 F = 0.195, p = .837 739 ± 138 1727 ± 639 720 ± 121 F = 2.57, p = .100
LF power  (ms2) 881 ± 171 1200 ± 658 863 ± 153 F = 0.161, p = .862 2352 ± 813 1839 ± 604 1445 ± 531 F = 0.519, p = .602
HF power  (ms2) 1581 ± 805 1842 ± 962 1521 ± 866 F = 4.66, p = .177 1286 ± 459 1837 ± 596 1695 ± 702 F = 0.287, p = .753
LF/HF power (%) 82.6 ± 52.9 63.9 ± 2.4 92.3 ± 62.6 F = 0.169, p = .855 260 ± 89.2 122 ± 16.2 115 ± 23.8 F = 2.32, p = .122
Normalized LF 
power
0.40 ± 0.17 0.39 ± 0.01 0.42 ± 0.19 F = 0.020, p = .981 0.56 ± 0.07 0.52 ± 0.03 0.49 ± 0.04 F = 0.636, p = .539
Normalized HF 
power
0.60 ± 0.17 0.60 ± 0.01 0.58 ± 0.19 F = 0.014, p = .987 0.44 ± 0.07 0.47 ± 0.03 0.51 ± 0.04 F = 0.636, p = .539
BRS (ms/mmHg) 22.5 ± 9.2 18.8 ± 2.5 20.8 ± 11 F = 0.176, p = .851 16.0 ± 1.9 15.3 ± 1.7 12.9 ± 1.7 F = 1.48, p = .249
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increasing access to electronic entertainment [9, 48, 49]. 
Hitherto, however, few studies have investigated the effects 
of prolonged sleep restriction on parameters related to the 
integrated stress response. Moreover, the results of these 
earlier studies have been inconsistent [37–40]. The novelty 
of the present study is the usage of a design that reflects 
accumulating sleep restriction during five long working 
days followed by 2 days of weekend recovery sleep, adding 
thereby to the ecological validaty of these earlier results.
The main results of this study show that heart rate 
increased after 5 days of restricted sleep, and also after the 
2 days recovery period. Blood pressure, however, remained 
unaffected. Since both blood pressure and heart rate are 
regulated by the autonomic sympatho-adrenal system, the 
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observed differences in those parameters may seem unex-
pected. Heart rate, however, changes more acutely than 
blood pressure, and healthy blood vessels respond by dila-
tion to prevent a rise in blood pressure. Hence, the observed 
absence of an increase in blood pressure is indicative of 
a good initial vascular health in our study population and 
does not mean that the autonomic activity did remain unaf-
fected. In fact, the increase in heart rate suggests increased 
sympathetic activity. Therefore, if the period of sleep 
restriction would have been extended to several weeks, it 
cannot be ruled out that this eventually would have resulted 
in increased blood pressure as well, such as for example 
observed by Tochikubo et al. in a healthy population [40] or 
Lusardi et al. in a hypertensive population [50].
The study population in the current study was young and 
healthy. Therefore, conclusions as to how a less healthy or 
older population would have been affected cannot be drawn. 
It is not unlikely, though, that the effects in that case would 
have been more serious, due to, for instance, a reduction in 
cardiovascular flexibility [51]. Elevated heart rate in itself, 
however, is already a major risk factor for the development 
of cardiovascular diseases, including hypertension and ath-
erosclerosis [52].
Another parameter that reflects the activity of the auto-
nomic sympatho-adrenal system is heart rate variability. 
The high-frequency (HF) component, ranging from 0.15 
to 0.4 Hz, represents the frequency of respiration and is 
mediated by the parasympathetic branch of the autonomic 
nervous system. The low-frequency (LF) component 
(0.04–0.15 Hz) reflects inputs from both the sympathetic 
and the parasympathetic branch of the ANS. As a conse-
quence, the LF/HF power ratio is an acceptable and widely 
used measure of sympathetic modulation [45, 53], despite 
that some studies do not agree with this interpretation [54]. 
Although short-term heart rate and blood pressure vari-
ability remained unaffected in the present study, the LF/
HF power ratio over the whole day was increased after five 
nights of sleep restriction. This is in line with the observed 
heart rate increase and also indicative of increased activity 
in the autonomic sympatho-adrenal system after a period 
of short sleep. Moreover, it is in line with results that were 
obtained by Zhong et al. in an acute sleep deprivation setting 
[36] as well as those of Dettoni and colleagues in a setting of 
less than 5 h sleep for a period of five nights [39].
Cortisol and neuropeptide Y are well-known stress hor-
mones that usually elevate in a similar way in response to 
acute stress [55]. It has also been suggested that NPY pro-
motes sleep, but the interaction between cortisol and NPY 
remains unclear [56, 57].
In the present study, they indeed responded in a simi-
lar way to sleep restriction, which is their levels were not 
affected. Particularly regarding salivary cortisol, which is 
a widely studied stress indicator, this is in line with some 
studies [37], but not in line with other studies of partial sleep 
restriction [38]. It has been hypothesized and shown that 
sleep disturbing and/or restricting protocols can result in 
lowered morning, but higher evening levels of cortisol, i.e., 
decreased amplitude of the rhythm [58]. Despite our sepa-
rate analyses of morning values and afternoon/evening val-
ues, we did not observe either of those effects. This may, of 
course, indicate that 5 days of restricted sleep is insufficient 
to elicit a clear stress response and that a clear response 
might have followed if sleep restriction was prolonged fur-
ther. Another interesting explanation might be in the timing 
of the 4 h time in bed that participants were allowed. Most 
studies place this period right in the middle of the habitual 
time in bed, thus delaying bedtime with 2 h and advancing 
wake up time with 2 h, e.g., [38, 59]. Although such studies 
may have valid reasons to do so, it does result in wake up 
times that are in or very near the circadian trough, namely 
at 0500 hours. It might be that waking up per se at such an 
inconvenient time, rather than at a more usual 0700 hours, 
results in additional stress responses in participants. Hence, 
in such studies, not only sleep is restricted, but also wake up 
time is advanced to what arguably is a very uncomfortable 
time to rise. Therefore, we can certainly not rule out that the 
cortisol results of the present study would have been more 
in line with previous work (i.e., showing a decreased ampli-
tude), if we had shifted the time in bed period 2 h back to 
0100–0500 hours instead of 0300–0700 hours. Indeed, it has 
been shown in several studies that early awakenings per se 
result in cortisol elevation throughout the entire day [60, 61].
In conclusion, we showed that the effects of 1 week of 
sleep restriction on the autonomic system in a young and 
healthy study population are limited. Both heart rate and 
whole day heart rate variability were increased in a manner 
suggesting increased sympathetic activity. Those are also the 
first parameters in which such an increase would be notice-
able. Other, possibly more serious, changes, such as those in 
blood pressure, may simply require more time to develop. Of 
special interest may be the discrepancy in cortisol responses 
between the present study and some of the previous studies, 
which might be solely attributable to the manner in which 
time in bed was scheduled. Finally, the possibility cannot be 
ruled out that more severe consequences would have been 
observed in an older and/or less healthy study population 
due to reduced cardiovascular flexibility [51] as well as 
when the current study would have been prolonged reflect-
ing several working weeks in a row, thereby better reflecting 
the prolonged effects of sleep restriction.
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